<DOC>
	<DOCNO>NCT01874743</DOCNO>
	<brief_summary>Participating country : France Objectives Principal objective To evaluate , HIV-1 infect patient receive effective antiretroviral therapy , effect addition Rosuvastatin ( dose 20mg/day ) 3 month , CD8 T cell activation assess proportion peripheral CD8 T cell co-express activation marker CD38 HLA-DR Secondary objective To evaluate effect Rosuvastatin administration residual CD4 CD8 T cell activation To evaluate effect Rosuvastatin administration main serum soluble biomarkers activation ( CRP- HS , D-dimers , IL-6 soluble CD14 ) To evaluate effect Rosuvastatin administration CD4 T-cell count CD4/CD8 T-cell ratio To study relationship level immune activation level residual HIV replication plasma To study effect Rosuvastatin administration lipid profile correlation HDL cholesterol CD4/CD8 T-cell ratio To evaluate tolerance Rosuvastatin dose 20 mg/day</brief_summary>
	<brief_title>Rosuvastatin Decrease Residual Immune Activation HIV Infection</brief_title>
	<detailed_description>Methodology Phase II pilot study ; open-label ; non comparative , bicentric , on-off design Estimated enrolment 40 subject Outcomes Primary outcome : • Variation month 3 proportion CD8 T lymphocytes co-expressing CD38 HLA-DR Secondary outcome : - Evolution plasma/serum level CRP-HS , IL-6 , soluble CD14 baseline month 3 month 3 month 6 - Evolution marker CD4 T-cell activation ( HLA-DR , Ki67 ) CD8 T-cell activation ( CD38 , HLA-DR , Ki67 ) baseline month 3 month 3 month 6 evolution CD4/CD8 ratio baseline month 3 month 3 month 6 - Evolution CD4 T-cell count baseline month 3 - Evolution HDL LDL cholesterol baseline month 3 month 3 month 6 - Relationship HDL cholesterol CD4/CD8 ratio baseline , month 3 month 6 - Relationship level T-cell activation plasma HIV-RNA level detection level 3 copies/mL - Adverse event grade &gt; 2 Eligibility Inclusion criterion - HIV-infected patient receive combination antiretroviral therapy least 24 month , unchanged since least 18 month , exhibit plasma HIV-RNA level 20 copy circulate CD4 T cell count 500/mm3 - No indication treatment statin ( LDL cholesterol &lt; 4.1 mmol/L stable diet ) . Non-inclusion criterion - Patients receive Maraviroc - Patients receive immune suppress drug - Ongoing opportunistic , bacterial viral infection - CRP ≥ 10 mg/mL - Co-infection HCV ( except HCV cure ) , chronic HBV infection active replication HBV - Indication treatment statins - Pregnancy - CPK &gt; 3x Normal value - ALT AST &gt; 2x Normal value - TG &gt; 4 mmol/L - DFG &lt; 60 mL /min/1.73 m2 - Personal familial history genetic muscular disease - History muscular hepatic toxicity statin fibrate - Liver disease ( TP &lt; 70 % ) . - Hypothyroidism - Concomitant treatment : Kétoconazole , Itraconazole , Ciclosporine , Erythromycine , Cimétidine , Quinidine , Diltiazem , Vérapamil , systemic corticosteroid , Phénobarbital , Phénytoïne , Carbamazépine , Rifampicine , Lansoprazole - Vaccination study Intervention Rosuvastatin ( 20 mg/d per o ) Intervention duration : 3 month Follow-up 3 additional month Statistical method Bilateral Two-sided pair Wilcoxon analyze variation proportion CD8 T lymphocytes co-express CD38 HLA-DR month 3 ( primary outcome ) . The evolution parameter interest 2 visit also analyze use bilateral two-sided pair Wilcoxon test . Statistical significance consider p &lt; 0.05 . Substudies Estimated plan Study / Trial timetable Trial/study start date : April 2012 Enrolment period : 12 month Subject participation duration : 6 month Total trial/study duration : 18 month Estimated study/trial completion date : October 2013 [ default date : date last follow-up last included patient , else justify chosen date : date `` gel de la base de données '' , date end substudies analyse ( think delay sample transport , duration technical analysis ) ] Study / Trial design Phase II open-label pilot bicentric non comparative study . Patients eligible receive Rosuvastatin 3 month continue antiretroviral therapy . Patients followed-up 3 additional month stop study drug ( on-off design )</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>HIVinfected patient receive combination antiretroviral therapy least 24 month , unchanged since least 18 month , exhibit plasma HIVRNA level 20 copy circulate CD4 T cell count 500/mm3 No indication treatment statin ( LDL cholesterol &lt; 4.1 mmol/L stable diet ) . Patients receive Maraviroc Patients receive immune suppress drug Ongoing opportunistic , bacterial viral infection CRP ≥ 10 mg/mL Coinfection HCV ( except HCV cure ) , chronic HBV infection active replication HBV Indication treatment statins Pregnancy CPK &gt; 3x Normal value ALT AST &gt; 2x Normal value TG &gt; 4 mmol/L DFG &lt; 60 mL /min/1.73 m2 Personal familial history genetic muscular disease History muscular hepatic toxicity statin fibrate Liver disease ( TP &lt; 70 % ) . Hypothyroidism Concomitant treatment : Kétoconazole , Itraconazole , Ciclosporine , Erythromycine , Cimétidine , Quinidine , Diltiazem , Vérapamil , systemic corticosteroid , Phénobarbital , Phénytoïne , Carbamazépine , Rifampicine , Lansoprazole Vaccination study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>HIV ,</keyword>
	<keyword>Rosuvastatine ,</keyword>
	<keyword>Antiretroviral therapy</keyword>
</DOC>